Alnylam Pharmaceuticals (NASDAQ:ALNY) has filed a marketing applicationin Europe seeking approval of RNAi therapeutic givosiran for the treatment of acute hepatic porphyria, a group of four rare inherited liver disorders characterized by intense abdominal pain over a period of one-to-two weeks.
Monday, July 1, 2019
Cerecor’s CERC-301 shows encouraging action in early-stage hypotension study
Results from a Phase 1 dose-escalating clinical trial evaluating Cerecor’s (NASDAQ:CERC) CERC-301 in patients with neurogenic orthostatic hypotension (a sudden drop in blood pressure when the person stands up) showed a positive effect.
Participants receiving the 20 mg dose, the highest tested, showed clinically meaningful improvements in blood pressure throughout the study.
On the safety front, there were no serious adverse events reports and all doses were considered safe and well-tolerated.
CERC-301 is an NR2B subunit-specific NMDA receptor antagonist. NMDA receptor overactivation is associated with a range of neurodegenerative diseases, including Parkinson’s.
Development is ongoing.
Shares are up 10% premarket on light volume.
Atara’s ATA188 shows favorable safety profile in early-stage MS study
Preliminary results from a Phase 1 study assessing Atara Biotherapeutics’ (NASDAQ:ATRA) ATA188 in patients with progressive multiple sclerosis (MS) demonstrated an encouraging safety profile. The data were presented at the European Academy of Neurology Annual Congress in Oslo.
Results from the first three dose cohorts showed no dose-limiting toxicities and no serious treatment-emergent adverse events.
The study is ongoing. The primary objective is to identify the optimal dose for a Phase 2 trial.
ATA188 is an allogeneic Epstein-Barr virus (EBV) cytotoxic T lymphocyte (CTL) immunotherapy that targets EBV antigens that the company believes play a key role in the treatment of MS.
Pfizer’s crisaborole ointment safe in infants and toddlers
Results from a Phase 4 study, CrisADe CARE 1, evaluating Pfizer’s (NYSE:PFE) crisaborole ointment 2% in young children aged three months to less than 24 months with mild-to-moderate atopic dermatitis (AD) showed a safety profile consistent with earlier studies.
Detailed data will be submitted for presentation at future medical conference.
Crisaborole ointment, branded as Eucrisa, is currently approved in select countries, including the U.S., for the treatment of mild-to-moderate AD in patients at least two years old.
Shares are up 1% premarket on light volume.
Biogen’s Spinraza shows long-term effect in mid-stage SMA study
Results from an open-label Phase 2 clinical trial, NURTURE, evaluating Biogen’s (NASDAQ:BIIB) Spinraza (nusinersen) in 25 presymptomatic patients with spinal muscular atrophy (SMA) showed a long-term treatment benefit. The data are being presented at the Cure SMA Annual SMA Conference in Anaheim, CA and the European Academy of Neurology Annual Congress in Oslo.
After 45.1 months of analysis, all treated patients were alive without the need for permanent ventilation and all were sitting independently. 88% were walking independently.
No new safety signals were reported.
The FDA approved the survival motor neuron-2-directed antisense oligonucleotide for the treatment of SMA in December 2016.
Shares are up 1% premarket on light volume.
Related ticker: Ionis Pharmaceuticals (NASDAQ:IONS)
United Therapeutics upped to Outperform by Credit Suisse
From Neutral
https://www.benzinga.com/stock/UTHR/ratings
https://www.benzinga.com/stock/UTHR/ratings
Subscribe to:
Posts (Atom)